Soliqua 100/33 is a combination medication used to treat type 2 diabetes. It contains two active ingredients: insulin glargine and lixisenatide [1]. Insulin glargine is a long-acting insulin, and lixisenatide is a glucagon-like peptide-1 (GLP-1) receptor agonist [2]. This dual action helps to lower blood glucose levels [1].
What is Soliqua 100/33 used for?
Soliqua 100/33 is indicated for adults with type 2 diabetes who have not achieved adequate glycemic control with basal insulin alone or with a GLP-1 receptor agonist alone [3]. It is intended to be used in conjunction with diet and exercise [1].
How does Soliqua 100/33 work?
The insulin glargine component in Soliqua 100/33 works by slowing down the rate of glucose release from the liver and increasing glucose uptake by fat and muscle cells [2]. The lixisenatide component enhances insulin secretion from the pancreas in response to high blood glucose, suppresses glucagon secretion, slows gastric emptying, and may reduce appetite [4].
When does Soliqua 100/33 lose patent protection?
The patent landscape for Soliqua 100/33 involves patents on the drug itself, its formulation, and its uses. Information on specific patent expiry dates and potential challenges can be found through resources like DrugPatentWatch.com [5]. Patent expiry is a critical factor in the potential market entry of generic or biosimilar versions of the drug.
Who makes Soliqua 100/33?
Soliqua 100/33 is manufactured by Sanofi [1].
What are the potential side effects of Soliqua 100/33?
Common side effects of Soliqua 100/33 include hypoglycemia (low blood sugar), nausea, vomiting, diarrhea, abdominal pain, and upper respiratory tract infections [3]. Serious side effects can include pancreatitis, severe allergic reactions, and vision problems [3]. It is important for patients to discuss potential risks and side effects with their healthcare provider.
How does Soliqua 100/33 compare to other diabetes medications?
Soliqua 100/33 offers a combination of a basal insulin and a GLP-1 receptor agonist, which may provide more comprehensive glycemic control for some patients compared to monotherapy with either agent [2]. It is a different approach than oral medications or other injectable insulin types. Comparisons to specific drugs like Trulicity or Victoza would depend on the individual patient's treatment goals and response [6].
Are there any alternatives to Soliqua 100/33?
Alternatives for type 2 diabetes management include other basal insulins, rapid-acting insulins, other GLP-1 receptor agonists, dipeptidyl peptidase-4 (DPP-4) inhibitors, sodium-glucose cotransporter-2 (SGLT2) inhibitors, and metformin [6]. The choice of alternative depends on individual patient factors, including disease severity, comorbidities, and previous treatment responses.
Sources:
[1] https://www.soliqua100-33.com/
[2] https://www.drugpatentwatch.com/news/soliqua-100-33-patent-information
[3] https://www.drugs.com/soliqua.html
[4] https://www.drugpatentwatch.com/drug/lixisenatide
[5] https://www.drugpatentwatch.com/
[6] https://www.drugpatentwatch.com/blog/soliqua-100-33-vs-competitors